LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
29 funds hold it · Insiders net selling
Net selling: insiders sold $8M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $16K to $65K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 5, 2026
Period ending
Sep 30, 2026
Earnings per share
$1.20 expected
Estimates as of Nov 11, 2026
EPS expected
$1.31 to $1.39
Revenue expected
14 analysts
Last 30 days
Analysts cutting estimates
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 5, 2026 | $1.23est. $1.20 | +2.77%beat | $763.7MSEC filing | -0.7%from $769.0M |
| Jun 30, 2026Reported Aug 6, 2026 | $1.34est. $1.10 | +21.91%beat | $789.6MSEC filing | +5.9%from $745.3M |
| Mar 31, 2026Reported May 7, 2026 | $1.12est. $0.92 | +21.73%beat | $759.9MSEC filing | +27.0%from $598.1M |
| Dec 31, 2025Reported Feb 24, 2026 | $1.28est. $1.15 | +10.96%beat | $826.4MAlpha Vantage | +25.7%from $657.3M |
| Sep 30, 2025Reported Nov 6, 2025 | $1.18est. $0.78 | +51.28%beat | $769.0MSEC filing | +22.9%from $625.7M |
| Jun 30, 2025Reported Aug 7, 2025 | $0.86est. $0.76 | +13.16%beat | $745.3MSEC filing | +18.4%from $629.7M |
| Mar 31, 2025Reported May 8, 2025 | $0.68est. $0.75 | -9.33%miss | $598.1MSEC filing | -1.4%from $606.7M |
| Dec 31, 2024Reported Feb 20, 2025 | $0.84est. $0.75 | +12.21%beat | $657.3MAlpha Vantage | +6.6%from $616.5M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $826.4M | $759.9M | $789.6M | $763.7M |
| Cost of what it sold | $231.3M | $234.1M | $241.4M | $232.9M |
| Gross profit | $595.1M | $525.8M | $548.2M | $530.8M |
| What it spent | ||||
| Research and development | $73.9M | $36.5M | $36.3M | $34.5M |
| Sales and admin | $318.5M | $297.8M | $286.8M | $288.5M |
| Other operating costs | $31.1M | $29.5M | $42.6M | $30.3M |
| Total operating expenses | $423.4M | $363.8M | $365.7M | $353.3M |
| What was left | ||||
| Operating profit | $171.7M | $163.6M | $182.4M | $177.6M |
| Interest on debt | — | $5.4M | — | — |
| Profit before tax | $174.1M | $157.1M | $189.8M | $183.3M |
| Tax | $33.4M | $32.8M | $38.2M | $42.1M |
| Net profit | $140.6M | $124.3M | $151.6M | $141.2M |
| EBITDA | $244.4M | $226.9M | $259.3M | $253.6M |
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bearish
Favorable Market Position and Emerging Surgical Technologies Underscore Globus Medical’s Narrow Moat
NeutralNov 6Globus Medical director Ann Rhoads sells $425,000 in shares By Investing.com
Leans bearishNov 6Globus Medical director Ann Rhoads sells $425,000 in shares By Investing.com
Leans bearishNov 6Globus Medical Boosts Share Buyback Program by $500M and Reports Q3 2026 Financial Results
BullishNov 6At $85 a share, director Ann D. Rhoads sells 5,000 Globus Medical (GMED) shares.
Leans bearishNov 5Vanguard reports a stake below 5% in Globus Medical (GMED).
NeutralOct 30BlackRock reports a Globus Medical (GMED) stake with sole voting power over 10.3M shares.
NeutralOct 2733 macro signals shaping GMED right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
